Your browser is no longer supported. Please, upgrade your browser.
Settings
BMRN BioMarin Pharmaceutical Inc. daily Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.50 Insider Own0.50% Shs Outstand177.73M Perf Week2.69%
Market Cap17.00B Forward P/E- EPS next Y-0.02 Insider Trans-11.54% Shs Float177.30M Perf Month11.39%
Income-87.30M PEG- EPS next Q-0.24 Inst Own- Short Float5.57% Perf Quarter-7.86%
Sales1.50B P/S11.36 EPS this Y88.70% Inst Trans0.09% Short Ratio9.75 Perf Half Y-6.12%
Book/sh16.42 P/B5.83 EPS next Y95.30% ROA-2.70% Target Price120.30 Perf Year7.34%
Cash/sh8.12 P/C11.78 EPS next 5Y47.20% ROE-4.40% 52W Range75.81 - 106.74 Perf YTD12.34%
Dividend- P/FCF- EPS past 5Y14.70% ROI-1.30% 52W High-10.38% Beta1.65
Dividend %- Quick Ratio2.30 Sales past 5Y21.30% Gross Margin78.90% 52W Low26.18% ATR3.38
Employees2581 Current Ratio2.90 Sales Q/Q17.20% Oper. Margin-1.80% RSI (14)59.08 Volatility3.21% 3.87%
OptionableYes Debt/Eq0.41 EPS Q/Q0.60% Profit Margin-8.40% Rel Volume1.42 Prev Close97.69
ShortableYes LT Debt/Eq0.28 EarningsFeb 21 AMC Payout- Avg Volume1.01M Price95.66
Recom1.90 SMA207.46% SMA503.71% SMA2001.50% Volume1,434,587 Change-2.08%
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18Initiated Wolfe Research Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $126
Aug-07-18Reiterated Stifel Buy $109 → $114
Aug-03-18Reiterated Stifel Buy $102 → $109
May-16-18Initiated Canaccord Genuity Buy $101
Jan-18-18Resumed Credit Suisse Outperform $113
Oct-06-17Resumed Goldman Buy $129
Sep-15-17Initiated RBC Capital Mkts Sector Perform $93
Sep-14-17Initiated Piper Jaffray Overweight $113
Aug-31-17Initiated Citigroup Buy $98
Aug-17-17Initiated Evercore ISI Outperform $100
Mar-30-17Initiated UBS Neutral $92
Mar-02-17Initiated Instinet Neutral $93
Feb-07-17Initiated Morgan Stanley Overweight $110
Jan-23-17Resumed Credit Suisse Outperform
Dec-08-16Initiated Gabelli & Co Buy $109
Nov-07-16Downgrade Piper Jaffray Overweight → Neutral
Nov-03-16Initiated Deutsche Bank Buy $106
Aug-05-16Reiterated Stifel Buy $107 → $113
Jan-17-19 03:07PM  6 Stocks Beating the Market GuruFocus.com
Jan-15-19 07:30AM  This is how much Apple pays a typical employee and how that compares to Google, Facebook, Netflix, Microsoft, Box and more American City Business Journals
Jan-14-19 10:40AM  Is BioMarin Pharmaceutical Stock a Bargain? Motley Fool
Jan-11-19 10:59AM  Why Sarepta Therapeutics Stock Is Starting to Shine Again InvestorPlace
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-09-19 07:39AM  The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study Benzinga
Jan-07-19 11:55AM  BioMarin Highlights Key Milestones for 2019 at 37th Annual J.P. Morgan Healthcare Conference in San Francisco PR Newswire
Jan-06-19 09:32AM  Outlook For Battered Biotech Stocks In 2019 Investopedia
Dec-18-18 08:55AM  Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved Benzinga
08:30AM  BioMarin to Present at 37th Annual J.P. Morgan Healthcare Conference in San Francisco PR Newswire
Dec-16-18 03:07AM  Argentiere Capitals Returns, AUM and Holdings Insider Monkey
Dec-13-18 05:18PM  Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay American City Business Journals
Dec-12-18 07:59AM  Is BioMarin Pharmaceutical Inc.s (NASDAQ:BMRN) CEO Paid Enough Relative To Peers? Simply Wall St.
Dec-10-18 07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
Dec-09-18 09:48AM  Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. (BMRN) Insider Monkey
Dec-07-18 07:30AM  Analysis: Positioning to Benefit within BioMarin Pharmaceutical, Ritchie Bros. Auctioneers, ADTRAN, Aspen Technology, AMC Entertainment, and Halliburton Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-06-18 09:20AM  Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger Zacks
Dec-03-18 01:47PM  BioMarin Promotes Amy Wireman to Group Vice President, Human Resources PR Newswire
08:30AM  BioMarin to Participate in Citi's 13th Annual Biotech Conference on December 5 in New York City PR Newswire
Nov-29-18 05:45PM  Bayer will shift hemophilia drug work to Berkeley, but won't add jobs American City Business Journals
04:00PM  Why Catalyst Pharmaceuticals Stock Is Sinking Today Motley Fool
01:39PM  Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma Investor's Business Daily
Nov-28-18 06:23PM  U.S. FDA approves Catalyst Pharma's rare disease drug Reuters
Nov-23-18 09:03AM  Sarepta Stock More Than Doubles This Year So Far: Here's Why Zacks
Nov-21-18 02:05PM  BioMarin sets stage early for haemophilia cure off-Broadway Reuters
01:54PM  RPT-FOCUS-BioMarin sets stage early for hemophilia cure off-Broadway Reuters
01:01AM  FOCUS-BioMarin sets stage early for hemophilia cure off-Broadway Reuters
Nov-16-18 08:22AM  A grandpa's hope for hemophilia cure leads him to gene therapy clinical trial CNBC
Nov-14-18 08:19AM  Sangamo stock drops after J.P. Morgan downgrade MarketWatch
Nov-12-18 02:30PM  BioMarin and Believe Limited Announce the Debut of 'Hemophilia: The Musical' PR Newswire
Nov-08-18 08:30AM  BioMarin to Participate in Two Investor Conferences in November PR Newswire
08:00AM  10 Health Care Stocks Seen Jumping on Takeovers Investopedia
Nov-07-18 09:10AM  BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York PR Newswire
Nov-01-18 08:30AM  BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York PR Newswire +5.73%
Oct-31-18 10:07AM  BioMarin Keeps on Pace for Its $2 Billion Goal Motley Fool
Oct-30-18 08:20AM  Research Report Identifies Deckers Outdoor, Navient, Phillips 66, BioMarin Pharmaceutical, McKesson, and Equity Residential with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-27-18 02:06AM  Edited Transcript of BMRN earnings conference call or presentation 25-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
Oct-26-18 01:05PM  BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates Zacks
08:17AM  The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default Benzinga
02:51AM  Biomarin Pharmaceutical Inc (BMRN) Q3 2018 Earnings Conference Call Transcript Motley Fool
Oct-25-18 05:29PM  BioMarin: 3Q Earnings Snapshot Associated Press
04:05PM  BioMarin Announces Third Quarter 2018 Results PR Newswire
Oct-22-18 07:30AM  Microsoft's typical worker makes $168K a year how that compares with Facebook, Google, PayPal, Box, Salesforce, Intel and other big Bay Area tech employers American City Business Journals
06:00AM  3 Biotech Stocks Poised to Rise by 15% or More Investopedia
Oct-21-18 05:15PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs Benzinga
Oct-17-18 08:00AM  Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Tesaro ACCESSWIRE
Oct-16-18 12:57PM  BioMarin Receives Milestone Payments from Pfizer for Talzenna® (Talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation PR Newswire +6.60%
Oct-11-18 05:16PM  BioMarin and Believe Limited Announce Selection of 25 High School Students to Perform in First-of-its-Kind 'Hemophilia: The Musical' PR Newswire
04:03PM  Forbes Names BioMarin Among World's Best Employers PR Newswire
Oct-08-18 02:50PM  Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area American City Business Journals
Oct-05-18 05:20PM  Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area American City Business Journals
Oct-04-18 08:30AM  BioMarin to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Thursday, October 25 at 4:30pm ET PR Newswire
Oct-03-18 02:06AM  With Hemlibra, Roche seeks to break into tight hemophilia circle Reuters
Sep-19-18 08:30AM  BioMarin to Participate in Two Investor Conferences in October PR Newswire
Sep-14-18 12:34PM  When Will BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Become Profitable? Simply Wall St.
Sep-06-18 08:48AM  Sangamo's Zinc Fingers Fail Again. Time to Walk Away? Motley Fool
Sep-05-18 03:20PM  How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease Investor's Business Daily
08:30AM  BioMarin Announces 20 Poster Presentations at Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018 PR Newswire
Sep-03-18 01:23PM  Why Sangamo Therapeutics Shot 33.7% Higher in August Motley Fool
Aug-22-18 08:30AM  BioMarin to Participate in Three Investor Conferences in September PR Newswire
Aug-20-18 06:05PM  Edited Transcript of BMRN earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-17-18 09:51PM  Is Spark Therapeutics a Bad News Buy? Motley Fool
12:27PM  3 Tough-Luck Tumbles in Healthcare: Are They Buys? Motley Fool
Aug-15-18 06:00AM  What's Next for Spark Therapeutics Motley Fool
Aug-13-18 08:00AM  3 Biotech Stock Favorites to Bet on Today: Top Analysts TheStreet.com
Aug-08-18 03:10PM  Backed with $140M, startup launches three-pronged attack on liver diseases American City Business Journals
09:15AM  NASDAQ, S&P Within 1% of New Highs Zacks
08:53AM  BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 7.9% Zacks
08:15AM  The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict Benzinga
07:59AM  Despite Recent Volatility, Biotech Stocks Look Poised to Pop Investopedia
Aug-07-18 04:43PM  Why Spark Therapeutics' Crash On Hemophilia A Led This Rival To Pop Investor's Business Daily +7.93%
03:32PM  8 Biotechs Still Worth Buying After a Sector Surge Barrons.com
02:10PM  BioMarin Pharmaceutical Sets Its Sights on $2 Billion Motley Fool
08:46AM  Spark Therapeutics stock plummets 28% premarket on hemophilia trial's patient safety concerns MarketWatch
07:30AM  Spark Therapeutics shares lose a third of their value as hemophilia gene therapy trial disappoints CNBC
Aug-03-18 11:05AM  BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat Zacks
Aug-02-18 06:00PM  BioMarin Pharmaceutical (BMRN) Q2 Earnings Miss Estimates Zacks
05:35PM  BioMarin Dips On Mixed Second Quarter But Sales Outlook In Line Investor's Business Daily
04:53PM  BioMarin: 2Q Earnings Snapshot Associated Press
04:05PM  BioMarin Announces Second Quarter 2018 Results PR Newswire
02:30PM  BioMarin Pharmaceutical Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 10:48AM  Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More Zacks
Jul-30-18 10:48AM  BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-26-18 08:00AM  Free Technical Insights on BioPharmX and Three Other Biotech Stocks ACCESSWIRE
Jul-11-18 08:30AM  BioMarin to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Thursday, August 2 at 4:30pm ET PR Newswire
Jul-09-18 11:30AM  Gene Therapy: BioMarin, Spark Can Both Win Treating Hemophilia Barrons.com
08:30AM  BioMarin Partners with Believe Limited for 'Breaking Through!' Musical Theater Intensive PR Newswire
Jul-05-18 10:32AM  Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns Zacks
Jul-03-18 05:11PM  Rare disease drug maker BioMarin's unusual path to campus expansion in Marin: Team up with a local senior center American City Business Journals
Jul-02-18 08:20AM  Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Arena Pharmaceuticals ACCESSWIRE
Jun-28-18 08:30AM  BioMarin Announces First Recipients of RARE Scholars Scholarship Program PR Newswire
Jun-27-18 07:35AM  Report: Developing Opportunities within American Homes 4 Rent, Invitation Home, Graphic Packaging Holding, Flotek Industries, Sunstone Hotel Investors, and BioMarin Pharmaceutical Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-19-18 07:00AM  Free Technical Research on BioPharmX and Three More Biotech Equities bio ACCESSWIRE
Jun-18-18 08:46AM  BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 8.5% Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Geron Corporation and BioMarin Pharmaceutical ACCESSWIRE
Jun-15-18 10:52AM  BioMarin Begins Pediatric Study on Achondroplasia Candidate Zacks +8.47%
07:30AM  3 Biotech Stocks Up in the Past Month on Industry Turnaround InvestorPlace
Jun-14-18 08:30AM  BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia PR Newswire
Jun-07-18 09:45AM  Why I Just Bought These 3 Stocks Motley Fool
08:15AM  BioMarin Receives Milestone Payments from Pfizer for Talazoparib PR Newswire
BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Option Exercise14.394,00057,560292,290Jan 15 07:43 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Sale93.794,000375,160288,290Jan 15 07:43 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise14.393,00043,170291,290Jan 11 03:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale90.553,000271,650288,290Jan 11 03:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Option Exercise14.396,00086,340294,290Jan 10 06:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Sale91.596,000549,523288,290Jan 10 06:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Option Exercise14.393,00043,170291,290Jan 09 02:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Sale87.583,000262,740288,290Jan 09 02:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Option Exercise14.393,00043,170291,290Jan 02 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Sale84.043,000252,120288,290Jan 02 05:24 PM
LAWLIS V BRYANDirectorDec 27Option Exercise14.392,15030,93921,310Dec 28 06:23 PM
LAWLIS V BRYANDirectorDec 27Sale82.532,150177,44019,160Dec 28 06:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Option Exercise14.394,00057,560292,290Dec 27 05:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Sale80.504,000322,000288,290Dec 27 05:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 14Option Exercise17.862,00035,720290,290Dec 18 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 14Sale92.642,000185,280288,290Dec 18 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 12Option Exercise17.862,00035,720290,290Dec 14 02:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 12Sale93.122,000186,240288,290Dec 14 02:44 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerNov 14Option Exercise63.109,000567,90058,135Nov 16 07:14 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerNov 14Sale92.159,000829,35949,135Nov 16 07:14 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 02Option Exercise17.861,50026,790289,790Nov 05 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 02Sale97.881,500146,820288,290Nov 05 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 01Option Exercise14.394,00057,560292,290Nov 02 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 01Sale92.554,000370,200288,290Nov 02 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 30Option Exercise14.391,00014,390288,290Nov 01 07:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Option Exercise14.391,00014,390287,290Oct 26 06:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 03Option Exercise17.861,50026,790287,790Oct 05 05:42 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerOct 03Sale98.981,00098,98549,135Oct 05 06:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 03Sale99.361,500149,040286,290Oct 05 05:42 PM
LAWLIS V BRYANDirectorSep 27Option Exercise14.392,15030,93921,310Sep 28 07:02 PM
LAWLIS V BRYANDirectorSep 27Sale97.932,150210,55019,160Sep 28 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 25Option Exercise14.391,00014,390286,290Sep 27 01:58 PM
Davis George EricEVP, General CounselSep 14Sale99.452,216220,38672,734Sep 18 04:42 PM
MEIER RICHARD ADirectorSep 13Option Exercise21.5115,000322,65084,610Sep 17 07:22 PM
MEIER RICHARD ADirectorSep 13Sale99.243,000297,72281,610Sep 17 07:22 PM
Davis George EricEVP, General CounselSep 13Sale99.5712,0001,194,84074,950Sep 17 06:57 PM
HERON ELAINE JDirectorSep 05Sale96.941,00096,93541,685Sep 07 02:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 04Option Exercise17.861,50026,790286,790Sep 06 05:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 04Sale98.161,500147,240285,290Sep 06 05:41 PM
LEWIS ALANDirectorAug 28Option Exercise14.397,500107,92528,660Aug 30 01:55 PM
LEWIS ALANDirectorAug 28Sale99.117,500743,32721,160Aug 30 01:55 PM
MEIER RICHARD ADirectorAug 27Option Exercise14.3915,000215,85071,610Aug 29 03:51 PM
MEIER RICHARD ADirectorAug 27Sale100.122,000200,23569,610Aug 29 03:51 PM
FUCHS HENRY JPresident, Worldwide R&DAug 27Sale100.0012,5001,250,000130,167Aug 28 05:54 PM
FUCHS HENRY JPresident, Worldwide R&DAug 24Sale99.0012,5001,237,500142,667Aug 28 05:54 PM
LEWIS ALANDirectorAug 21Sale100.094,200420,36521,160Aug 22 07:06 PM
Mueller BrianSVP, Corporate ControllerAug 07Option Exercise28.232,50070,57514,875Aug 09 04:27 PM
BAFFI ROBERTEVP, Technical OperationsAug 07Sale105.005,173543,16571,882Aug 09 04:58 PM
Mueller BrianSVP, Corporate ControllerAug 07Sale104.502,500261,25012,375Aug 09 04:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 23Option Exercise17.861,50026,790286,790Jul 25 07:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 23Sale101.691,500152,535285,290Jul 25 07:47 PM
LAWLIS V BRYANDirectorJun 27Option Exercise14.392,15030,93921,310Jun 29 05:59 PM
LAWLIS V BRYANDirectorJun 27Sale93.522,150201,06819,160Jun 29 05:59 PM
Mueller BrianSVP, Corporate ControllerJun 22Option Exercise28.232,49170,32114,866Jun 26 08:15 PM
BAFFI ROBERTEVP, Technical OperationsJun 22Option Exercise14.396,94999,99690,225Jun 26 08:23 PM
BAFFI ROBERTEVP, Technical OperationsJun 22Sale99.006,949687,95483,276Jun 26 08:23 PM
Mueller BrianSVP, Corporate ControllerJun 22Sale99.503,145312,92812,375Jun 26 08:15 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 22Sale99.0010,000990,00551,070Jun 26 08:31 PM
Mueller BrianSVP, Corporate ControllerJun 15Sale94.502,021190,98513,029Jun 18 08:30 PM
FUCHS HENRY JPresident, Worldwide R&DJun 14Option Exercise34.4331,0001,067,380175,848Jun 18 08:11 PM
FUCHS HENRY JPresident, Worldwide R&DJun 14Sale90.0031,0002,790,085155,167Jun 18 08:11 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 13Option Exercise14.391,00014,390285,290Jun 14 07:53 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 11Sale90.311,436129,68550,135Jun 13 06:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Option Exercise38.5918,750723,563309,350May 18 06:15 PM
MEIER RICHARD ADirectorMay 17Option Exercise38.5915,000578,85051,310May 18 06:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Sale88.6618,7501,662,356290,600May 18 06:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 16Option Exercise38.5918,750723,563309,350May 17 08:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 16Sale89.1318,7501,671,131290,600May 17 08:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 15Option Exercise38.5918,750723,563309,350May 16 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 15Sale88.2918,7501,655,434290,600May 16 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 14Option Exercise38.5918,750723,563309,350May 16 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 14Sale89.2218,7501,672,851290,600May 16 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 11Option Exercise38.5918,750723,563309,350May 14 09:28 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 11Sale88.4218,7501,657,856290,600May 14 09:28 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Option Exercise38.5918,750723,563309,350May 14 09:28 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Sale89.5918,7501,679,794290,600May 14 09:28 PM
Mueller BrianSVP, Corporate ControllerMay 10Sale89.502,450219,27515,396May 14 08:43 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 07Sale85.9630926,56252,914May 09 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 24Option Exercise38.5910,000385,900300,031Apr 25 08:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 24Sale82.2910,000822,887290,031Apr 25 08:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Option Exercise38.5910,000385,900300,031Apr 25 08:30 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerApr 23Sale82.1511,059908,49762,543Apr 25 08:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Sale82.5810,000825,811290,031Apr 25 08:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 20Option Exercise38.5910,000385,900300,031Apr 24 07:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 20Sale83.6510,000836,458290,031Apr 24 07:50 PM
LAWLIS V BRYANDirectorApr 17Option Exercise38.593,750144,71318,610Apr 19 07:19 PM
LAWLIS V BRYANDirectorApr 17Sale85.003,750318,75014,860Apr 19 07:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Option Exercise14.391,00014,390290,031Apr 09 03:51 PM
FUCHS HENRY JPresident, Worldwide R&DApr 02Option Exercise33.7910,000337,851163,326Apr 03 08:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 02Option Exercise14.391,00014,390289,031Apr 03 08:56 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 02Sale80.122,119169,77452,914Apr 03 09:00 PM
FUCHS HENRY JPresident, Worldwide R&DApr 02Sale80.1210,000801,200156,676Apr 03 08:51 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 29Sale79.691,537122,48455,033Mar 30 08:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 28Option Exercise16.132,00032,250288,031Mar 30 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 27Option Exercise14.391,00014,390286,031Mar 28 06:36 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 26Option Exercise14.391,00014,390285,031Mar 28 06:36 PM
Davis George EricEVP, General CounselMar 23Sale81.353,350272,52387,989Mar 27 06:17 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 22Option Exercise14.391,00014,390297,106Mar 26 07:27 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 21Sale83.904,368366,47560,153Mar 23 04:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Option Exercise38.5915,000578,850311,106Mar 20 07:46 PM